H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of $10.00. Patrick Trucchio’s rating is based on Sangamo ...

TD Cowen analyst Ritu Baral has maintained their bullish stance on SGMO stock, giving a Buy rating yesterday. Ritu Baral has given her Buy ...

Good afternoon and welcome to the Sangamo Therapeutics Third Quarter 2024 Teleconference Call. Please be advised that today's conference is being recorded. I would now like to turn the conference over ...

RBC Capital Mkts has recently reduced Sangamo Therapeutics Inc (SGMO) stock to Sector Perform rating, as announced on November 3, 2023, according to Finviz. Earlier, on April 28, 2023, BofA Securities ...

Key regulatory milestones and financial updates position Sangamo Therapeutics Inc (SGMO) for potential growth despite funding ...

CHICAGO — The former chief lobbyist for electric utility Commonwealth Edison has spent the last week telling a federal jury ...

RICHMOND, Calif., November 12, 2024 -- ( BUSINESS WIRE )--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial ...

(SGMO) on Tuesday reported third-quarter earnings of $10.7 million. On a per-share basis, the Richmond, California-based company said it had profit of 4 cents. The results exceeded Wall Street ...

Sangamo Therapeutics SGMO is preparing to release its quarterly earnings on Tuesday, 2024-11-12. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

On Friday, Sangamo Therapeutics Inc (SGMO) stock saw a modest uptick, ending the day at $2.87 which represents a slight increase of $0.06 or 2.14% from the prior close of $2.81. The stock opened at $2 ...